Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?

Rossi E, Schinzari G, Zizzari IG, Maiorano BA, Pagliara MM, Sammarco MG, Fiorentino V, Petrone G, Cassano A, Rindi G, Bria E, Blasi MA, Nuti M, Tortora G.

Cancers (Basel). 2019 Jul 26;11(8). pii: E1055. doi: 10.3390/cancers11081055. Review.

2.

First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome.

Chiloiro S, Capoluongo ED, Schinzari G, Concolino P, Rossi E, Martini M, Cocomazzi A, Grande G, Milardi D, Maiorano BA, Giampietro A, Rindi G, Pontecorvi A, De Marinis L, Bianchi A.

Front Endocrinol (Lausanne). 2019 Jun 12;10:365. doi: 10.3389/fendo.2019.00365. eCollection 2019.

3.

Pembrolizumab as first-line treatment for metastatic uveal melanoma.

Rossi E, Pagliara MM, Orteschi D, Dosa T, Sammarco MG, Caputo CG, Petrone G, Rindi G, Zollino M, Blasi MA, Cassano A, Bria E, Tortora G, Schinzari G.

Cancer Immunol Immunother. 2019 Jul;68(7):1179-1185. doi: 10.1007/s00262-019-02352-6. Epub 2019 Jun 7.

4.

No evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with 223Radium.

De Vincentis G, Frantellizzi V, Follacchio GA, Farcomeni A, Pani A, Samaritani R, Schinzari G, Santini D, Cortesi E.

Eur J Cancer Care (Engl). 2019 May 31:e13112. doi: 10.1111/ecc.13112. [Epub ahead of print]

PMID:
31148330
5.

Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions.

Iacovelli R, Ciccarese C, Schinzari G, Maiorano BA, Rossi E, Pierconti F, Bassi PF, Bria E, Tortora G.

Crit Rev Oncol Hematol. 2019 Jul;139:83-86. doi: 10.1016/j.critrevonc.2019.05.005. Epub 2019 May 11. Review.

PMID:
31112886
6.

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma.

Rossi E, Maiorano BA, Pagliara MM, Sammarco MG, Dosa T, Martini M, Rindi G, Bria E, Blasi MA, Tortora G, Schinzari G.

Front Oncol. 2019 Apr 5;9:232. doi: 10.3389/fonc.2019.00232. eCollection 2019.

7.

Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?"

Di Noia V, Vita E, Ferrara M, Strippoli A, Basso M, Schinzari G, Cassano A, Bria E, Barone C, D'Argento E.

Curr Treat Options Oncol. 2019 Feb 21;20(3):23. doi: 10.1007/s11864-019-0616-7. Review.

PMID:
30790063
8.

The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer.

Cianci R, Franza L, Schinzari G, Rossi E, Ianiro G, Tortora G, Gasbarrini A, Gambassi G, Cammarota G.

Int J Mol Sci. 2019 Jan 24;20(3). pii: E501. doi: 10.3390/ijms20030501. Review.

9.

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.

Bersanelli M, Giannarelli D, Castrignanò P, Fornarini G, Panni S, Mazzoni F, Tiseo M, Rossetti S, Gambale E, Rossi E, Papa A, Cortellini A, Lolli C, Ratta R, Michiara M, Milella M, De Luca E, Sorarù M, Mucciarini C, Atzori F, Banna GL, La Torre L, Vitale MG, Massari F, Rebuzzi SE, Facchini G, Schinzari G, Tomao S, Bui S, Vaccaro V, Procopio G, De Giorgi U, Santoni M, Ficorella C, Sabbatini R, Maestri A, Natoli C, De Tursi M, Di Maio M, Rapacchi E, Pireddu A, Sava T, Lipari H, Comito F, Verzoni E, Leonardi F, Buti S.

Immunotherapy. 2018 Oct;10(14):1229-1239. doi: 10.2217/imt-2018-0080.

PMID:
30326787
10.

Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study.

Rindi G, Klersy C, Albarello L, Baudin E, Bianchi A, Buchler MW, Caplin M, Couvelard A, Cros J, de Herder WW, Delle Fave G, Doglioni C, Federspiel B, Fischer L, Fusai G, Gavazzi F, Hansen CP, Inzani F, Jann H, Komminoth P, Knigge UP, Landoni L, La Rosa S, Lawlor RT, Luong TV, Marinoni I, Panzuto F, Pape UF, Partelli S, Perren A, Rinzivillo M, Rubini C, Ruszniewski P, Scarpa A, Schmitt A, Schinzari G, Scoazec JY, Sessa F, Solcia E, Spaggiari P, Toumpanakis C, Vanoli A, Wiedenmann B, Zamboni G, Zandee WT, Zerbi A, Falconi M.

Neuroendocrinology. 2018;107(4):375-386. doi: 10.1159/000494355. Epub 2018 Oct 9.

11.

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.

Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, Ruscito I, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M.

Cancer Immunol Res. 2018 Jun;6(6):711-722. doi: 10.1158/2326-6066.CIR-17-0594. Epub 2018 Apr 26.

12.

Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis.

Inno A, Di Noia V, Martini M, D'Argento E, Di Salvatore M, Arena V, Schinzari G, Orlandi A, Larocca LM, Cassano A, Barone C.

Pathol Oncol Res. 2019 Apr;25(2):513-520. doi: 10.1007/s12253-018-0404-x. Epub 2018 Mar 20.

PMID:
29557085
13.

Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?

Rossi S, Di Noia V, Tonetti L, Strippoli A, Basso M, Schinzari G, Cassano A, Leone A, Barone C, D'Argento E.

Future Oncol. 2018 Apr;14(10):919-926. doi: 10.2217/fon-2017-0499. Epub 2018 Mar 12.

PMID:
29528255
14.

Is 18F-Fluorodeoxyglucose the Tracer of Choice for Functional Imaging of Neuroendocrine Tumors Grade 3? A Case Report.

Lorusso M, Inzani F, Castaldi P, Menghi R, Schinzari G, Rindi G, Rufini V.

Pancreas. 2018 Apr;47(4):e20-e22. doi: 10.1097/MPA.0000000000001012. No abstract available.

PMID:
29521949
15.

Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium.

Schinzari G, Rossi E, Pierconti F, Garufi G, Monterisi S, Strippoli A, D'Argento E, Cassano A, Barone C.

Oncotarget. 2018 Jan 11;9(9):8765-8771. doi: 10.18632/oncotarget.24162. eCollection 2018 Feb 2.

16.

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.

Rinzivillo M, Fazio N, Pusceddu S, Spallanzani A, Ibrahim T, Campana D, Marconcini R, Partelli S, Badalamenti G, Brizzi MP, Catena L, Schinzari G, Carnaghi C, Berardi R, Faggiano A, Antonuzzo L, Spada F, Gritti S, Femia D, Gelsomino F, Bongiovanni A, Ricci S, Brighi N, Falconi M, Delle Fave G, Panzuto F.

Pancreatology. 2018 Mar;18(2):198-203. doi: 10.1016/j.pan.2018.01.005. Epub 2018 Jan 12.

PMID:
29361429
17.

The risk of malignancy of atypical urothelial cells of undetermined significance in patients treated with chemohyperthermia or electromotive drug administration.

Pierconti F, Rossi ED, Straccia P, Fadda G, Larocca LM, Bassi PF, Sacco E, Schinzari G.

Cancer Cytopathol. 2018 Mar;126(3):200-206. doi: 10.1002/cncy.21957. Epub 2018 Jan 23.

18.

Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies.

Rossi S, Cassano A, Strippoli A, Schinzari G, D'Argento E, Basso M, Barone C.

Drugs Context. 2017 Nov 8;6:212506. doi: 10.7573/dic.212506. eCollection 2017.

19.

Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.

Schinzari G, Rossi E, Cassano A, Dadduzio V, Quirino M, Pagliara M, Blasi MA, Barone C.

Melanoma Res. 2017 Dec;27(6):591-595. doi: 10.1097/CMR.0000000000000401.

PMID:
29076951
20.

Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.

Schinzari G, Monterisi S, Pierconti F, Nazzicone G, Marandino L, Orlandi A, Racioppi M, Cassano A, Bassi P, Barone C, Rossi E.

Anticancer Res. 2017 Nov;37(11):6453-6458.

PMID:
29061832
21.

RUNX3 as a Potential Predictor of Metastasis in Human Pancreatic Cancer.

Rossi E, Bagalà C, Inzani F, Leoncini E, Brunelli C, Lanza P, Basso M, Mattiucci GC, Cassano A, Rindi G, Barone C, Schinzari G.

In Vivo. 2017 Sep-Oct;31(5):833-840.

22.

First-line Treatment of Advanced Biliary Ducts Carcinoma: A Randomized Phase II Study Evaluating 5-FU/LV Plus Oxaliplatin (Folfox 4) Versus 5-FU/LV (de Gramont Regimen).

Schinzari G, Rossi E, Mambella G, Strippoli A, Cangiano R, Mutignani M, Basso M, Cassano A, Barone C.

Anticancer Res. 2017 Sep;37(9):5193-5197.

PMID:
28870954
23.

Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study.

Chiloiro S, Lanza F, Bianchi A, Schinzari G, Brizi MG, Giampietro A, Rufini V, Inzani F, Giordano A, Rindi G, Pontecorvi A, De Marinis L.

Endocrine. 2018 May;60(2):362-367. doi: 10.1007/s12020-017-1327-0. Epub 2017 May 31.

PMID:
28567607
24.

DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer.

Di Noia V, Basso M, Marsico V, Cerchiaro E, Rossi S, D'Argento E, Strippoli A, Schinzari G, Iezzi R, Cassano A, Barone C.

Future Oncol. 2019 Jul;15(20):2349-2360. doi: 10.2217/fon-2017-0025. Epub 2017 Apr 25.

PMID:
28440086
25.

Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy.

Quirino M, Rossi S, Schinzari G, Basso M, Strippoli A, Cassano A, Barone C.

Medicine (Baltimore). 2017 Apr;96(16):e6522. doi: 10.1097/MD.0000000000006522.

26.

Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer?

Rossi S, Basso M, Strippoli A, Schinzari G, D'Argento E, Larocca M, Cassano A, Barone C.

Clin Colorectal Cancer. 2017 Dec;16(4):264-274. doi: 10.1016/j.clcc.2017.03.015. Epub 2017 Mar 24. Review.

PMID:
28412137
27.

IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.

Di Salvatore M, Pietrantonio F, Orlandi A, Del Re M, Berenato R, Rossi E, Caporale M, Guarino D, Martinetti A, Basso M, Mennitto R, Santonocito C, Mennitto A, Schinzari G, Bossi I, Capoluongo E, Danesi R, de Braud F, Barone C.

Oncotarget. 2017 Mar 7;8(10):16887-16898. doi: 10.18632/oncotarget.14810.

28.

Erratum to: From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?

D'Argento E, Rossi S, Schinzari G, Strippoli A, Basso M, Cassano A, Barone C.

Curr Treat Options Oncol. 2016 Dec;17(12):65. No abstract available.

PMID:
27995578
29.

From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?

D'Argento E, Rossi S, Schinzari G, Strippoli A, Basso M, Cassano A, Barone C.

Curr Treat Options Oncol. 2016 Dec;17(12):59. Review. Erratum in: Curr Treat Options Oncol. 2016 Dec;17 (12 ):65.

PMID:
27766545
30.

Gastrointestinal stromal tumors (GISTs) and second malignancies: A novel "sentinel tumor"? A monoinstitutional, STROBE-compliant observational analysis.

Rodriquenz MG, Rossi S, Ricci R, Martini M, Larocca M, Dipasquale A, Quirino M, Schinzari G, Basso M, D'Argento E, Strippoli A, Barone C, Cassano A.

Medicine (Baltimore). 2016 Sep;95(38):e4718. doi: 10.1097/MD.0000000000004718.

31.

Are TKIs favourable for the elderly with non-small-cell lung cancer?

Rossi S, D'Argento E, Schinzari G, Dadduzio V, Di Noia V, Cassano A, Barone C.

Oncotarget. 2016 Jul 26;7(30):46871-46877. doi: 10.18632/oncotarget.9389.

32.

ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis.

Strippoli A, Rossi S, Martini M, Basso M, D'Argento E, Schinzari G, Barile R, Cassano A, Barone C.

Oncotarget. 2016 Jun 7;7(23):35159-68. doi: 10.18632/oncotarget.9063.

33.

Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review.

Rossi S, Schinzari G, Basso M, Strippoli A, Dadduzio V, D'Argento E, Cassano A, Barone C.

Future Oncol. 2016 May;12(10):1299-307. doi: 10.2217/fon-2015-0065. Epub 2016 Mar 21. Review.

PMID:
26996100
34.

KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study.

Dadduzio V, Basso M, Rossi S, Cenci T, Capodimonti S, Strippoli A, Orlandi A, Cerchiaro E, Schinzari G, Cassano A, Martini M, Barone C.

Mol Diagn Ther. 2016 Feb;20(1):65-74. doi: 10.1007/s40291-015-0178-8.

PMID:
26610798
35.

Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.

Rossi S, Basso M, Strippoli A, Dadduzio V, Cerchiaro E, Barile R, D'Argento E, Cassano A, Schinzari G, Barone C.

Clin Breast Cancer. 2015 Oct;15(5):307-12. doi: 10.1016/j.clbc.2015.03.010. Epub 2015 Mar 25. Review.

PMID:
25922284
36.

The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?

Pantano F, Santoni M, Procopio G, Rizzo M, Iacovelli R, Porta C, Conti A, Lugini A, Milella M, Galli L, Ortega C, Guida FM, Silletta M, Schinzari G, Verzoni E, Modica D, Crucitti P, Rauco A, Felici A, Ballatore V, Cascinu S, Tonini G, Carteni G, Russo A, Santini D.

PLoS One. 2015 Apr 17;10(4):e0120427. doi: 10.1371/journal.pone.0120427. eCollection 2015.

37.

Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.

Schinzari G, Monterisi S, Signorelli D, Cona MS, Cassano A, Danza F, Barone C.

Tumori. 2014 Nov-Dec;100(6):e298-300. doi: 10.1700/1778.19304.

PMID:
25688515
38.

Targeted therapy in advanced gastric carcinoma: the future is beginning.

Schinzari G, Cassano A, Orlandi A, Basso M, Barone C.

Curr Med Chem. 2014;21(8):1026-38. Review.

PMID:
24304282
39.

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients.

Basso M, Strippoli A, Orlandi A, Martini M, Calegari MA, Schinzari G, Di Salvatore M, Cenci T, Cassano A, Larocca LM, Barone C.

Br J Cancer. 2013 Jan 15;108(1):115-20. doi: 10.1038/bjc.2012.526. Epub 2012 Nov 22.

40.

Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity.

Basso M, Modoni A, Spada D, Cassano A, Schinzari G, Lo Monaco M, Quaranta D, Tonali PA, Barone C.

Cancer Chemother Pharmacol. 2011 May;67(5):1179-87. doi: 10.1007/s00280-010-1466-y. Epub 2010 Sep 25.

PMID:
20872144
41.

Temsirolimus: is improved survival the correct expression of drug activity?

Basso M, Cassano A, Schinzari G, Barone C.

Oncologist. 2010;15(7):790-1; author reply 792. doi: 10.1634/theoncologist.2010-0099. No abstract available.

42.

Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.

Rossi B, Schinzari G, Maccauro G, Scaramuzzo L, Signorelli D, Rosa MA, Fabbriciani C, Carlo B.

BMC Musculoskelet Disord. 2010 Feb 16;11:34. doi: 10.1186/1471-2474-11-34.

43.

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study).

Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G, Artale S, Mutri V, Giaquinta S, Giannetta L, Bardelli A, Martoni AA.

Br J Cancer. 2009 Oct 20;101(8):1261-8. doi: 10.1038/sj.bjc.6605319. Epub 2009 Sep 22.

44.

Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.

Landriscina M, Bagalà C, Piscazzi A, Schinzari G, Quirino M, Fabiano A, Bianchetti S, Cassano A, Sica G, Barone C.

Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.

PMID:
19152342
45.

7-Year survival results of perioperative chemotherapy with epidoxorubicin, etoposide, and cisplatin (EEP) in locally advanced resectable gastric cancer: up-to-date analysis of a phase-II study.

Persiani R, Rausei S, Pozzo C, Biondi A, Barone C, Cananzi FC, Schinzari G, D'Ugo D.

Ann Surg Oncol. 2008 Aug;15(8):2146-52. doi: 10.1245/s10434-008-9982-2. Epub 2008 Jun 10.

PMID:
18543037
46.

A reversible coma after oxaliplatin administration suggests a pathogenetic role of electrolyte imbalance.

Basso M, Cassano A, Modoni A, Spada D, Trigila N, Quirino M, Schinzari G, Barone C.

Eur J Clin Pharmacol. 2008 Jul;64(7):739-41. doi: 10.1007/s00228-008-0474-x. Epub 2008 Mar 19. No abstract available.

PMID:
18350285
47.

Role of chemotherapy in malignant thymoma.

Valente M, Schinzari G, Ricciotti A, Barone C.

Ann Ital Chir. 2007 Sep-Oct;78(5):377-80. Review.

PMID:
18338542
48.

Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.

Barone C, Nuzzo G, Cassano A, Basso M, Schinzari G, Giuliante F, D'Argento E, Trigila N, Astone A, Pozzo C.

Br J Cancer. 2007 Oct 22;97(8):1035-9. Epub 2007 Sep 25.

49.

Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer.

Barone C, Basso M, Schinzari G, Pozzo C, Trigila N, D'Argento E, Quirino M, Astone A, Cassano A.

Gastric Cancer. 2007;10(2):104-11. Epub 2007 Jun 25.

PMID:
17577620
50.

Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.

Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C.

Oncology. 2006;70(5):366-77. Epub 2006 Dec 15.

PMID:
17179731

Supplemental Content

Loading ...
Support Center